Spherical calcium phosphate nanoparticle fillers allow polymer processing of bone fixation devices with high bioactivity by Mohn, D et al.
University of Zurich





Spherical calcium phosphate nanoparticle fillers allow polymer
processing of bone fixation devices with high bioactivity
Mohn, D; Ege, D; Feldman, K; Schneider, O D; Imfeld, T; Boccaccini, A R; Stark, W
J
Mohn, D; Ege, D; Feldman, K; Schneider, O D; Imfeld, T; Boccaccini, A R; Stark, W J (2010). Spherical calcium
phosphate nanoparticle fillers allow polymer processing of bone fixation devices with high bioactivity. Polymer
Engineering and Science, 50(5):952-960.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Polymer Engineering and Science 2010, 50(5):952-960.
Mohn, D; Ege, D; Feldman, K; Schneider, O D; Imfeld, T; Boccaccini, A R; Stark, W J (2010). Spherical calcium
phosphate nanoparticle fillers allow polymer processing of bone fixation devices with high bioactivity. Polymer
Engineering and Science, 50(5):952-960.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Polymer Engineering and Science 2010, 50(5):952-960.
Spherical calcium phosphate nanoparticle fillers allow polymer
processing of bone fixation devices with high bioactivity
Abstract
Treatment of bone defects generally requires a fixation device. Biodegradable implants can often
prevent second operations in contrast to metallic implants that are surgically removed after healing. In
this study, we investigate the preparation of a bone fixation device with additional bioactivity by adding
nanoparticulate amorphous tricalcium phosphate (ATCP) to improve bonding to bone. Medically
approved poly(lactide-co-glycolide) (PLGA) and spherical (ATCP) nanoparticles were blended directly
or through a two-step approach, where ATCP was first dispersed in PLGA by solvent casting, extruded
and hot pressed producing blocks and bone screws. The latter route yielded good particle dispersion
while blending alone led to inhomogeneous mixtures. Samples were immersed in simulated body fluid
and showed rapid formation of surface hydroxyapatite layers (examined by X-ray diffraction and
scanning electron microscopy) already after 3 days, thus confirming very high bioactivity. Polymer
degradation during processing and upon simulated implantation conditions was followed by gel
permeation chromatography. The elevated temperature during extrusion was the strongest single factor
contributing to PLGA degradation. Screws could be machined out of extruded cylinders and
demonstrated the ability to process PLGA/ATCP 90/10 composites with regular workshop tools. These
properties suggest the use of such composites as improved, bioactive, and degradable bone fixation
systems particularly in oral and maxillofacial surgery. POLYM. ENG. SCI., 50:952-960, 2010. (C) 2009
Society of Plastics Engineers
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ABSTRACT 
Treatment of bone defects generally requires a fixation device. Biodegradable 
implants can often prevent second operations in contrast to metallic implants that are 
surgically removed after healing. In this study, we investigate the preparation of a 
bone fixation device with additional bioactivity by adding nanoparticulate amorphous 
tricalcium phosphate (ATCP) to improve bonding to bone. Medically approved 
poly(lactide-co-glycolide) (PLGA) and spherical (ATCP) nanoparticles were blended 
directly or through a two-step approach, where ATCP was first dispersed in PLGA by 
solvent casting, extruded and hot pressed producing blocks and bone screws. The 
latter route yielded good particle dispersion while blending alone led to 
inhomogeneous mixtures. Samples were immersed in simulated body fluid (SBF) and 
showed rapid formation of surface hydroxyapatite layers (examined by X-ray 
diffraction and scanning electron microscopy) already after 3 days, thus confirming 
very high bioactivity. Polymer degradation during processing and upon simulated 
implantation conditions was followed by gel permeation chromatography. The 
elevated temperature during extrusion was the strongest single factor contributing to 
PLGA degradation. Screws could be machined out of extruded cylinders and 
demonstrated the ability to process PLGA/ATCP 90/10 composites with regular 
workshop tools. These properties suggest the use of such composites as improved, 
bioactive, and degradable bone fixation systems particularly in oral and maxillofacial 
surgery. 
INTRODUCTION 
Biomedical composites are used in temporal or permanent implant materials 
and they have gained significant clinical interest due to their ability to integrate into 
the body [1-3]. The advantage of resorbable implants over metals lies in preventing 
subsequent operation for implant removal and reducing postoperative stress. 
Biodegradable materials are currently used in clinical applications as sutures or as 
orthopedic fixation devices i.e. screws or plates [1, 4-6] in oral and maxillofacial 
surgery [7]. Poly(lactide-co-glycolide) (PLGA) is one of the most often used 
biodegradable synthetic polymers [8]. PLGA is known for its biocompatibility [9, 10], 
the capability to support drug delivery [11], nerve regeneration [12] and its 
commercial use in bone surgery [8]. With ongoing degradation, the polymer 
undergoes several alterations which result in molecular weight loss, structural changes 
and reduction in strength and stiffness. The latter is appropriate for bone fracture 
fixation systems as the implant should only initially provide mechanical support. 
Polymer degradation successively reduces the mechanical performance and leads to a 
step by step transfer of load to the healing bone [1]. A potential drawback of 
degradation is the release of acidic degradation products that can lead to an 
inflammatory tissue response [13]. 
Biodegradable polymers by themselves are not bioactive and therefore, they 
can not actively bind to bone. One strategy to overcome the lack of biological 
attachment to bone of biodegradable polymers is to combine the advantages of 
polymers and an inorganic bioreactive phase, i.e. through addition of bioreactive 
fillers that render the polymer bioactive (bonding to bone-tissue through formation of 
hydroxyapatite structures on the polymer surface) [14]. Among possible bioreactive 
fillers for biodegradable polymers, calcium phosphates or bioactive glasses represent 
a common choice because they can induce rapid and strong bonding of the composite 
to bone [15-17]. Calcium phosphates are commercially available and widely used for 
their excellent biocompatibility and osteoconductivity [18]. Amorphous tricalcium 
phosphate (ATCP) has been reported as an exceptionally reactive precursor for the 
formation of hydroxyapatite [19, 20]. 
As an additional benefit, inorganic fillers can counteract and accordingly 
buffer the acidic degradation of some biopolymers, e.g. polylactides and 
polyglycolides, which otherwise cause inflammatory tissue response. Stabilization of 
pH around an implant is of particular interest [14] and has been demonstrated by the 
addition of alkaline compounds, for example calcium phosphates [16, 21] or bioactive 
glasses [22, 23]. Lin et al. [24] have shown that microsized and crystalline tricalcium 
phosphate (TCP) with low surface area used as filler in poly(α-hydroxy acids) 
resulted in decelerated degradation of the polymer and induced adverse mechanical 
properties during degradation [16]. A possibility to overcome this limitation can be 
the reduction of the filler particle size [25] to achieve enhanced dispersion and 
improved mode of action of tricalcium phosphate filler. Most recently, a significant 
improvement of bioactivity, degradation and mechanical properties of PLGA 
composites has been demonstrated by using nanosized instead of microsized ATCP 
fillers [26]. The induced nanostructured surface topography mimics the structure of 
natural bone, and resulted in higher protein adsorption [27], increased osteoblast 
function [28, 29] and an improved implant-tissue interaction [30]. It would therefore 
be of high clinical interest to apply the exceptional bioactivity of ATCP nanofillers in 
currently used plate/screw bone fixation devices. 
The study described in this paper investigates the production of 
PLGA/spherical-ATCP nanocomposite components with defined shape for orthopedic 
surgery. The study has been particularly motivated by recent observations on the 
improved bioactivity and controlled degradation of solvent-cast films (thickness: 120-
150 µm) of PLGA and spherical ATCP nanoparticles [26]. We used a combined 
dispersion and blending approach and produced for the first time polymer/ATCP 
nanoparticles composites via solvent casting and solid blocks by extrusion and hot 
pressing. The degradation process during the different processing steps was monitored 
by gel permeation chromatography. A high apatite mineralization on this bulk 
composite was confirmed by a short term in vitro bioactivity study. 
 
EXPERIMENTAL 
Preparation of amorphous tricalcium phosphate nanoparticles 
Amorphous tricalcium phosphate nanoparticles were prepared by flame spray 
synthesis [31] as described by Loher et al. [32]. Briefly, calcium hydroxide (Riedel de 
Haen, Ph. Eur.) dissolved in 2-ethylhexanoic acid (Sigma-Aldrich) and tributyl 
phosphate (98%, Sigma Aldrich) were used as precursors. The liquid precursor-
mixture was diluted with xylene to a final metal concentration of 0.8 mol l-1 and 
pumped (9 ml min-1) through a capillary (diameter 0.4 mm), dispersed with oxygen (9 
l min-1) and ignited by a methane/oxygen flame. The as-formed ATCP particles 
(production rate of 50 g h-1) were collected on bag-house filters and subsequently 
sieved (250 µm mesh). 
 
Production of ATCP/PLGA composite 
Clinically approved PLGA was purchased from Boehringer Ingelheim with a 
copolymer ratio of 85:15 (Resomer® Sample MD Type RG) with a weight and 
number average molecular weight of 305,440 and 110,500 g mol-1, respectively. A 
copolymer ratio of 85:15 was chosen due to a faster degradation than PLA while 
maintaining a reasonable degradation time and initial device stability. In order to 
disperse the ATCP nanoparticles in the polymer matrix, solvent casting [26] was 
applied prior to extrusion and hot pressing of the composite material. Composites with 
different weight ratios PLGA/ATCP (100/0, 90/10, 70/30) were produced using the 
aforementioned techniques. As-prepared ATCP nanoparticles were dispersed in 
chloroform (Riedel de Haen, Ph. Eur.) containing 5 % (w/w) Tween20 
(Polysorbate20, Fluka, Ph. Eur.) referred to PLGA using an ultrasonic processor 
(UP400S, Hielscher) at 320 W for 5 min applying pulsed intervals (50 %) to allow for 
relaxation of the particles. The polymer in concentration 8 % w/w (referred to the 
solvent) was added afterwards and dissolved during 15 h under continuous stirring. 
Composite solutions were cast on polypropylene moulds and the solvent evaporated 
during 48 h in desiccators at room temperature. The as-obtained films were cut and 
filled in a custom designed twin-screw extruder with a reflux cycle. Extrusion for 20 
minutes at a temperature of 200 °C resulted in a homogenous composite material (see 
below) that was cut subsequently into smaller pellets for hot-pressing blocks with the 
dimensions 7.5 x 5.1 x 1.6 mm (length, width and height). For further experiments 
these blocks were used as the raw template of a biomedical product. Two larger M6 
dimensioned screws (ISO standard 965) [33] containing 0 and 10 wt% ATCP 
nanoparticles in PLGA were machined using a turning lathe (Weiler E30) from a hot-
pressed cylindrical block with the dimensions of 9.5 x 25 mm (diameter and length). 
 
Characterization of ATCP particles and PLGA/ATCP composites 
The specific surface area (SSA) of ATCP particles was measured by nitrogen 
adsorption at 77 K according to the Brunauer-Emmett-Teller (BET) method using a 
Tristar 3000 (Micrometrics, Norcross, GA, USA) after out-gassing at 150 °C for 1 h. 
The primary particle diameter assuming spherical particles was calculated according 
to dBET = 6/(ρATCP•SSA). Particle size distributions were measured on a X-ray disk 
centrifuge (XDC) [34] (Brookhaven Instruments, Holtsville, NY, USA) using 1.5% 
(wt/vol) of powder dispersed in ethanol (Merck, Ph. Eur.) and the mean 
hydrodynamic particle diameter was denoted as dXDC. Prior to analysis the powder 
was dispersed by ultrasonication at 200 W for 5 min. A transmission electron 
microscope (TEM) (CM30 ST, LaB6 cathode, Philips Electron Optics, Eindhofen, the 
Netherlands), was operated at 300 kV with a point resolution of 0.4 nm to study the 
morphology and to confirm the particle size. Scanning electron microscopy (SEM) 
was used to characterize the bioactivity of ATCP nanoparticles, as well as the 
composite samples before and after in vitro degradation. The corresponding samples 
were placed on 12 mm diameter aluminum stubs and coated with 4 nm platinum prior 
to SEM analysis (LEO 1530 Gemini). X-ray diffraction (XRD) patterns were taken on 
a X’Pert PRO-MPD diffractometer (CuKα radiation, X’Celerator linear detector 
system, step size of 0.033°) at ambient conditions. 
 
Processing and in vitro degradation 
Degradation of neat PLGA and PLGA/ATCP composite was investigated 
during processing of the materials. Gel permeation chromatography (GPC) (Agilent 
1100 Series, 2 x Mixed-C, Polymer Lab, flow rate 1 ml/min, calibrated with 
polystyrene) using tetrahydrofurane (THF) as eluting solvent was performed to 
determine the reduction of molecular weight starting from the raw material (PLGA) 
until the final product, i.e. the composite block. Furthermore, the degradation of 
PLGA/ATCP (90/10) was monitored regarding its residence time in the extruder. 
 A short term in vitro bioactivity study was performed using simulated body 
fluid (SBF) according to Kokubo et al. [35]. Freshly prepared SBF was sterile filtrated 
through a Nalgene® pre-sterilized filter unit. The weight of the samples was recorded 
in triplicates before (W0) and after (Ww and Wd, see below) immersion in SBF for 3, 
7, 14 and 28 days at 37 °C. The SBF was exchanged every 7 days to guarantee a 
constant liquid composition. Before immersion, the samples were UV irradiated (50 
W m-2, 10 min) to ensure that no bacterial contamination contributed to the polymer 
degradation. After removal, samples were rinsed with Millipore water, the surface 
gently wiped and the wet weight recorded (Ww). Drying at room temperature in an 
evacuated desiccator overnight gave the dry weight (Wd). The mass difference (MD) 
and water uptake (WU) of the degraded blocks were determined by the following 
equations: MD = (Wd-W0) / W0 and WU = (Ww-Wd) / Wd, respectively. The 
composite samples after SBF immersion were analyzed using XRD and SEM to 
determine the in vitro bioactivity and the change of the surface morphology. 
Prior to GPC, all samples were dissolved in THF and the particle containing 
blocks were centrifuged. The supernatant was collected and examined by GPC. 
 
RESULTS 
Spherical and amorphous tricalcium phosphate nanoparticles were produced 
by flame spray synthesis (Figure 1a). The specific surface area of as prepared 
nanoparticles was 87.3 ± 0.3 m2g-1 resulting in a primary particle diameter (dBET) of 
22 nm assuming spherical particle shape. X-ray disk centrifugation (XDC) revealed a 
unimodal size distribution of ATCP nanoparticles with dXDC of 39 nm (Figure 1b). 
The average number of primary particles per aggregate np was estimated [36] to 2.8 
using the fractal relationship np = (dc/dp)D where dp denotes as primary particle 
diameter dBET, dc as collision diameter dXDC and D as fractal dimension of 1.8, which 
is consistent with nanoparticle formation in flame reactors [37]. X-ray diffraction 
(XRD) confirmed the amorphous state of the as-prepared powder by the absence of 
distinct reflections. After sintering (900 °C, 30 min) the distinct pattern of β-TCP was 
observed (Figure 1c). 
The used raw materials PLGA and ATCP (Figure 2a) resulted in a 
homogenous mixture after pre-dispersion, solvent casting and extrusion for 20 
minutes. The obtained pellets (Figure 2b) showed no separation of the ATCP 
nanoparticles and the initial granulate. The final shape manufactured by hot pressing 
yielded homogenous blocks of PLGA/ATCP composite. A cylinder with larger 
dimensions was processed to the final shape of a screw using PLGA/ATCP (100/0, 
90/10) composites (Figure 2c). The dispersion of ATCP nanoparticles at the surface of 
the composite differed between the pellets and hot pressed blocks (Figure 3). Due to 
the pre-dispersion of ATCP nanoparticles during the solvent casting step, the particles 
were homogenously dispersed in PLGA and also exposed at the surface (Figure 3a). 
After hot pressing, however, the particles were well embedded in the polymer matrix 
(Figure 3b). Reference experiments were made with dry mixtures of ATCP particles 
and PLGA granulates directly subjected to extrusion (no pre-dispersion or solvent 
casting step). These materials suffered from phase separation and did not become 
homogenous even after longer processing. 
The in vitro bioactivity of composite blocks containing ATCP nanoparticles 
was confirmed by the distinct pattern of hydroxyapatite (HA) in the X-ray 
diffractogram (XRD) at 31.8° (Figure 4). In contrast, pure PLGA showed no HA 
formation, assessed by SEM, in agreement with earlier studies [38] (Figure 5c). 
However, the surface of PLGA after extrusion, hot pressing and immersion in SBF up 
to 28 days examined with SEM indicated a surface morphology change. The PLGA 
pellets after extrusion showed a smooth surface (Figure 5a) compared to hot pressed 
blocks in which a certain surface roughness was observed (Figure 5b). Holes on the 
surface of PLGA blocks after immersion in SBF could be attributed to the dissolution 
of the water soluble surfactant Tween20 (Figure 5c) in agreement with results of 
Schneider et al. [38]. The surface change of composite blocks immersed in SBF, 
examined by SEM, confirmed HA formation already after 3 days (Figure 6). The 
amount of HA crystals increased with prolonged immersion time in SBF as 
qualitatively observed in Figures 6 (a-d). 
The water uptake of all composite samples increased with prolonged 
immersion time. A higher ATCP content further increased the water uptake resulting 
in 20 % for PLGA/ATCP 70/30 composite (Figure 7a). As a reference, the mass of 
pure PLGA blocks hardly changed during 28 days immersion in SBF. Intermediate 
samples showed a complex behavior. Blocks with 10 wt% of ATCP showed a mass 
gain of ~5 %, whilst samples with 30 wt% filler resulted in mass loss during 
prolonged immersion (Figure 7b) (see discussion below). 
Knowledge of polymer degradation is essential for optimizing processing 
conditions and for the final application as biomedical product. The number average 
molecular weight and weight average molecular weight decreased with increasing 
processing steps (Figure 7c). Both the number of processing steps and the duration of 
extrusion had an influence on the degree of degradation (Figure 7d) and underline the 
importance of pre-dispersion to keep extrusion times at an acceptable level.  
 
DISCUSSION 
Poly-lactides, -glycolides and their copolymers are widely used in orthopedics, 
for example for sutures [8] but internal fixation devices (plates, screws) are gaining 
increasing interest [1]. To enhance and modify the properties of applied biodegradable 
fixation devices, a number of fillers (e.g. calcium carbonate, tricalcium phosphate or 
hydroxyapatite) have been added to the polymer matrix [39-41]. The present study 
reports on the successful processing of a novel bioactive implant material based on 
PLGA and ATCP nanoparticles. 
A distinct advantage of using reactive ATCP nanoparticles is their enhanced 
solubility compared to crystalline phases of TCP that show little or no reactivity [42]. 
Nanosized ATCP reacts with water and enforces HA formation during re-
crystallization, according to: 
3 4 2 2 9 4 4 5 r3 Ca (PO )  + H O = Ca (HPO )(PO ) OH    Ä G: 30.1 kJ/mol  (1) 
The spherical nanoparticles are virtually un-agglomerated (see particle size data), 
which facilitates their incorporation in a polymer and further processing of the 
composite if compared to much larger, crystalline, microsized α- and β-TCP [43]. 
This enabled the preparation of composite pellets by twin screw extrusion with up to 
30 wt% inorganic filler. While direct blending resulted in phase separation, solvent 
casting as a pre-dispersion step allowed rapid and homogeneous dispersion [44] 
(Figure 3). Whilst longer residence times in an extruder might improve dispersion 
after direct blending, the degradation of polylactides at high temperatures [45, 46] 
disfavors such a strategy and highlights the need for a two-step preparation approach. 
 
Bioactivity and surface changes 
Neat PLGA pellets showed a smooth surface when compared to PLGA blocks 
directly after hot pressing (Figure 5). This minor roughness was caused by the 
moulds. In the case of the composites, the nanoparticles induced a certain surface 
roughness, reflecting altered stress relaxation and adhesion to machine walls. After 
degradation in SBF, pure PLGA exhibited small holes in the surface which were a 
result of the elution of water soluble surfactant Tween20 [38] (Figure 5c). The 
otherwise smooth surface supported no HA formation which was further confirmed by 
the absence of reflections in the XRD pattern even after 28 days in SBF (Figure 4). In 
contrast, both XRD and scanning electron microscopy (SEM) analysis confirmed the 
formation of HA crystals already after 3 days immersion in SBF for PLGA/ATCP 
70/30 composites. The surface change revealed the rapid formation of nanosized HA 
on the composite surfaces (Figure 6b and 6c). The fact that HA deposition occurred 
only on samples containing ATCP nanoparticles underlined the importance of ATCP 
as a reaction and nucleation site for HA formation [47, 48]. The broad diffraction 
signal resembles the nanosized and poorly crystalline HA in natural bone mineral 
[49]. Larger HA deposits were observed after 28 days of immersion in SBF, which 
entirely covered the surface of degraded composite blocks (Figure 6d). 
 
Composite degradation 
Two competing processes can alter the surface structure and composition of a 
bioactive composite. Polymer degradation and dissolution of calcium phosphate 
contributes to mass loss. In addition, it must be pointed out that ATCP nanoparticles 
first dissolve and then re-crystallize either on the composite’s surface (overall mass 
increases; see Figure 7b) or separately (the composite material loses mass and mineral 
deposits on the walls and bottom of the test container are found). The complexity of 
this mechanism is best illustrated using the (apparently contradicting) mass changes 
for composites with 10 and 30 wt% filler (Figure 7b). Mineralization is presumably 
switching between predominantly “separately” to “on the material’s surface”. The 
latter deposition of HA crystals obviously contribute to a mass increase (i.e. sample 
90/10). The mineral deposition on the surfaces of the biomaterial is a marker for in 
vitro bioactivity and enables the surrounding tissue to bind strongly to the implant 
material. The overall mass change can be used as an indicative measure for the 
combined action of polymer degradation and/or HA deposition and water uptake 
(swelling). Porosity was monitored for all composite samples during in vitro 
degradation in SBF up to 28 days (Figure 7a and 7b) by measuring the mass 
difference between wet and dry samples (water trapped in pores). For neat PLGA, 
hardly any mass change could be detected during 28 days, although the water 
absorption increased with prolonged immersion in SBF. The increased water 
absorption is due to the hydrophilic character of PLGA and its degradation products 
[50]. This is in agreement with little changes in surface topography and few polymer 
degradation. Adding ATCP nanoparticles as a filler resulted in a higher water 
absorption (Figure 7a) as a result of pore formation (dissolved filler particles leave 
pores in the material) and enhanced swelling of composite blocks (pores allow water 
to penetrate farther into the material). Loher et al. [26] have shown that water uptake 
did not increase for dense, pure, solvent cast PLGA films with a thickness of 120-150 
µm. In the present study, hot pressed blocks with a thickness of 1.6 mm were used. 
Pressed, granulate derived, pure PLGA is apparently porous enough to allow some 
water uptake during prolonged immersion. This observation is further supported by 
the findings of Ehrenfried et al. [50] who described a mechanism based on water 
absorption and on the actual polymer degradation in relation to different α-TCP 
quantities. The water content describes the balance between hydrated oligomers going 
into the solution and the water uptake to the residual mass [50] meaning that not only 
pore formation but also the accumulation of hydrolytic degradation products is 
responsible for the increasing water uptake of PLGA/ATCP 90/10 composites. The 
water uptake of PLGA/ATCP 70/30 composites reached a plateau which is similar to 
a most recent study [50]. Furthermore not only the water absorption but also the onset 
of mass loss can be shifted for higher calcium phosphate loadings. However, the here 
described polymer loss is lower due to the different copolymer ratio of 85:15 if 
compared to the 50:50 ratio in the study by Ehrenfried et al. [50] where one of the 
fastest degrading copolymer ratios of PLGA was used [8]. 
 
Polymer degradation during processing 
GPC revealed that the highest reduction in molecular weight occured during 
the processing steps when heat was applied: extrusion and hot pressing (Figure 7c and 
7d). This result is in agreement with the fact that PLGA degradation can be mainly 
attributed to the duration and heat exposure during material processing [51]. The 
extrusion time should therefore be kept as short as possible. Moisture and shear stress 
can additionally contribute to degradation and thereby affect the final mechanical 
properties [52]. As no stabilizers are allowed for implant materials (FDA guidelines), 
the processing parameters have to be controlled carefully to obtain the desired product 
properties. Since polymer degradation is both affected by mass transfer (availability 
of water) and thermodynamics (reaction kinetics of the polymer), the addition of an 
inorganic fillers has been reported to reduce both degradation rates in vitro [53, 54] or 
accelerate degradation through facilitated pore formation [26]. The present work uses 
a highly reactive filler; hence, degradation is likely to be accelerated through 
facilitated pore formation and faster water absorption. 
 
CONCLUSION 
The present study has enabled the combination of high bioactivity with easy 
processing for specific biodegradable bone implant devices based on PLGA and 
ATCP nanoparticles. This extends the potential application of highly bioactive 
polymers from simple composite films to complex 3D shaped, machinable biomedical 
composites. The incorporation and dispersion of spherical ATCP nanoparticles into 
the PLGA matrix induced nanostructured surface topography and enabled high 
surface reactivity with hydroxyapatite formation within days after implantation. The 
number of process steps and overall extrusion time are crucial for keeping polymer 
degradation within acceptable values. The present results suggest that PLGA/ATCP 
bone screws should be further evaluated pre-clinically and may be well suited as 
alternative elements to presently used, pure biodegradable polymer based devices or 
composites using microsized inorganic fillers. This study further demonstrated that 
suitably nanosized and shaped reactive inorganic fillers can be incorporated into 
biodegradable polymers by optimal processing conditions even at high filler content. 
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Figure 1: (a) Transmission electron microscopy image of as-prepared ATCP 
nanoparticles; (b) Hydrodynamic particle size distribution of ATCP nanoparticles 
measured with X-ray disc centrifugation; (c) X-ray diffraction pattern of as-prepared 
and sintered tricalcium phosphate nanoparticles. 
 Figure 2: (a) Image of raw materials for preparing the PLGA/ATCP nanocomposite: 
ATCP nanoparticles (0.1 g) and PLGA granulate (0.5 g); (b) Extruded pellets of 
PLGA/ATCP 100/0 (left), 90/10 (middle) and 70/30 (right) nanocomposite showing 
macroscopically a homogenous mixture; (c) processed screws out of a cylinder with 
PLGA/ATCP 90/10 composite (left) and a neat PLGA sample (right). 
 Figure 3: SEM images of the surface of PLGA/ATCP 70/30: extruded pellets (a) and 
hot pressed blocks (b), showing the ATCP dispersion at the surface (a) and ATCP 
nanoparticles embedded in the polymer matrix (b). 
  
Figure 4: X-ray diffraction patterns of PLGA before and after immersion in SBF for 
28 days indicating no hydroxyapatite formation. The patterns for PLGA/ATCP 70/30 
composites revealed the formation of nanocrystalline hydroxyapatite after immersion 
in SBF. 
  
Figure 5: SEM images of PLGA at different processing steps during the production, 
where (a) shows the smooth surface after extrusion, (b) is the surface after hot 
pressing a block and (c) presenting the degradation of PLGA after 28 days immersion 
in SBF showing holes in the surface. 
  
Figure 6: SEM images of PLGA/ATCP 70/30 composites after different times in SBF. 
(a) after 0 days, (b) after 3 days showing a rougher surface and hydroxyapatite 
formation, (c) close-up of image (b), (d) after 28 days showing larger hydroxyapatite 
deposition. 
  
Figure 7: (a) Water uptake of different PLGA/ATCP composite samples after 
immersion in SBF (* two specimens tested); (b) Mass change of nanocomposite 
samples as a function of immersion time in SBF up to 28 days (* two specimens 
tested). (c) Degradation of PLGA/ATCP 90/10 composite during processing from the 
raw material to the final sample shape measured by GPC; (d) GPC detected 
degradation of PLGA/ATCP 90/10 for different residence times in the twin-screw 
extruder. 
